She obtained her Ph.D. in Pharmacology from King's College, London in 1981, and since then the primary focus of her work has been cardiomyocyte function in the failing heart. This has extended to gene therapy to modulate cardiomyocyte function, and she is Scientific PI for the UK's first clinical trial on myocardial gene therapy. More recently the scope has extended to the characterisation of cardiomyocytes derived from embryonic stem cells, and their use in cardiac repair, tissue engineering and drug discovery.
Professor Harding is Past-President of the European Section of the International Society for Heart Research and Fellow of the AHA, ESC and ISHR. She sits on the Nuffield Council on Bioethics and the Scientific Advisory Board of the PPP "Stem Cells for Safer Medicines".
Professor Harding delivered her Inaugural Lecture, entitled 'Reviving the Failing Heart: one cell at a time', on 3 April 2007. The abstract and other details of the lecture can be found here.
Sattler S, Couch LS, Harding SE, 2018, Takotsubo Syndrome: Latest Addition to the Expanding Family of Immune-Mediated Diseases?, Jacc Basic Transl Sci, Vol:3, Pages:779-781
et al., 2018, Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTCI E99K Mutation Unveil Differential Functional Deficits, Stem Cell Reports, Vol:11, ISSN:2213-6711, Pages:1226-1243
Noseda M, Harding SE, 2018, Understanding dynamic tissue organization by studying the human body one cell at a time: the human cell atlas (HCA) project, Cardiovascular Research, Vol:114, ISSN:0008-6363, Pages:E93-E95
et al., 2018, Immunomodulatory interventions inmyocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition, Cardiovascular Research, Vol:114, ISSN:0008-6363, Pages:1445-1461
et al., 2018, Auxetic Cardiac Patches with Tunable Mechanical and Conductive Properties toward Treating Myocardial Infarction, Advanced Functional Materials, Vol:28, ISSN:1616-301X